Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (412) 412
Publication (78) 78
Book Chapter (4) 4
Conference Proceeding (4) 4
Patent (3) 3
Book / eBook (2) 2
Music Score (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
medicin och hälsovetenskap (336) 336
science & technology (282) 282
life sciences & biomedicine (260) 260
humans (246) 246
multiple sclerosis (241) 241
neurosciences & neurology (175) 175
female (154) 154
male (154) 154
neurosciences (149) 149
neurology (138) 138
clinical neurology (130) 130
adult (119) 119
middle aged (113) 113
multiple sclerosis - genetics (98) 98
medical and health sciences (90) 90
biological and medical sciences (80) 80
medical sciences (75) 75
immunology (63) 63
risk factors (63) 63
aged (55) 55
multiple sclerosis and variants. guillain barré syndrome and other inflammatory polyneuropathies. leukoencephalitis (54) 54
clinical medicine (53) 53
multiple sclerosis - epidemiology (52) 52
multiple sclerosis - immunology (51) 51
klinisk medicin (47) 47
genetic predisposition to disease (46) 46
registries (46) 46
genetic aspects (40) 40
sweden - epidemiology (40) 40
case-control studies (39) 39
research (37) 37
sweden (37) 37
young adult (37) 37
genotype (35) 35
alleles (34) 34
disease progression (33) 33
genetics (33) 33
neurologi (33) 33
abridged index medicus (31) 31
analysis (31) 31
medicine (31) 31
adolescent (30) 30
epidemiology (29) 29
genetics & heredity (29) 29
haplotypes (29) 29
sick leave (29) 29
cohort studies (26) 26
health sciences (26) 26
hälsovetenskaper (26) 26
folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi (24) 24
disability evaluation (23) 23
gene frequency (23) 23
multiple sclerosis - drug therapy (22) 22
public health, global health, social medicine and epidemiology (22) 22
prognosis (21) 21
polymorphism, single nucleotide (20) 20
research article (20) 20
science & technology - other topics (20) 20
studies (20) 20
treatment outcome (20) 20
hla-dr antigens - genetics (19) 19
multidisciplinary sciences (19) 19
patients (19) 19
age (18) 18
degenerative and inherited degenerative diseases of the nervous system. leukodystrophies. prion diseases (18) 18
disability (18) 18
risk (18) 18
time factors (18) 18
disability pension (17) 17
fundamental and applied biological sciences. psychology (17) 17
genetic predisposition to disease - genetics (17) 17
magnetic resonance imaging (17) 17
multiple sclerosis - pathology (17) 17
odds ratio (17) 17
disease (16) 16
genes (16) 16
linkage disequilibrium (16) 16
polymorphism, single nucleotide - genetics (16) 16
age of onset (15) 15
autoimmune diseases (15) 15
genetic susceptibility (15) 15
histocompatibility antigen hla (15) 15
medicine & public health (15) 15
multiple sclerosis - diagnosis (15) 15
phenotype (15) 15
biochemistry & molecular biology (14) 14
genetic linkage (14) 14
psychiatry (14) 14
allergy and immunology (13) 13
animals (13) 13
confidence intervals (13) 13
disease susceptibility (13) 13
gene expression (13) 13
genetic research (13) 13
genetics of eukaryotes. biological and molecular evolution (13) 13
genomes (13) 13
multiple sclerosis - blood (13) 13
multiple sclerosis - physiopathology (13) 13
population (13) 13
population studies (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Socioeconomic status and multiple sclerosis outcome
by Hillert, Jan
Nature reviews. Neurology, ISSN 1759-4758, 04/2020, Volume 16, Issue 4, pp. 191 - 192
Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Multiple Sclerosis | Humans | Social Class | Social classes | Multiple sclerosis | Demographic aspects | Health aspects | Patient outcomes | Health risk assessment | Socioeconomic factors | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
by Luna, Gustavo and Alping, Peter and Burman, Joachim and Fink, Katharina and Fogdell-Hahn, Anna and Gunnarsson, Martin and Hillert, Jan and Langer-Gould, Annette and Lycke, Jan and Nilsson, Petra and Salzer, Jonatan and Svenningsson, Anders and Vrethem, Magnus and Olsson, Tomas and Piehl, Fredrik and Frisell, Thomas
JAMA neurology, ISSN 2168-6149, 02/2020, Volume 77, Issue 2, pp. 184 - 191
Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Antiviral agents | Multiple sclerosis | Copolymer 1 | Medical treatment | World population | Health risks | Rituximab | Infections | Patients | Antibiotics | Risk assessment | Design modifications | Data collection | Interferon | Public health
Journal Article
Details down arrow
3. Full Text Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
by Alping, Peter and Askling, Johan and Burman, Joachim and Fink, Katharina and Fogdell‐Hahn, Anna and Gunnarsson, Martin and Hillert, Jan and Langer‐Gould, Annette and Lycke, Jan and Nilsson, Petra and Salzer, Jonatan and Svenningsson, Anders and Vrethem, Magnus and Olsson, Tomas and Piehl, Fredrik and Frisell, Thomas and Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap and Sahlgrenska akademin and Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
Annals of neurology, ISSN 0364-5134, 05/2020, Volume 87, Issue 5, pp. 688 - 699
Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Confidence intervals | Multiple sclerosis | Invasiveness | Health risks | Comparative studies | Rituximab | Population | Risk | Cancer | Index Medicus | Neurologi | Neurology | Neurovetenskaper | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Clinical course of multiple sclerosis: A nationwide cohort study
by Manouchehrinia, Ali and Beiki, Omid and Hillert, Jan
Multiple sclerosis, ISSN 1352-4585, 10/2017, Volume 23, Issue 11, pp. 1488 - 1495
disease course | Multiple sclerosis | disability progression | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Severity of Illness Index | Multiple Sclerosis - mortality | Humans | Middle Aged | Male | Multiple Sclerosis - epidemiology | Sweden - epidemiology | Disease Progression | Multiple Sclerosis - physiopathology | Adult | Female | Registries | Cohort Studies | Risk factors | Age | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes
by Piehl, Fredrik and Hillert, Jan
Multiple sclerosis, ISSN 1352-4585, 8/2018, Volume 24, Issue 9, pp. 1157 - 1159
Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Rituximab - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Immunologic Factors - therapeutic use | Multiple Sclerosis - drug therapy | Rituximab | Multiple sclerosis | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
by Holmén, Carolina and Piehl, Fredrik and Hillert, Jan and Fogdell-Hahn, Anna and Lundkvist, Malin and Karlberg, Elin and Nilsson, Petra and Dahle, Charlotte and Feltelius, Nils and Svenningsson, Anders and Lycke, Jan and Olsson, Tomas and Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
Multiple sclerosis, ISSN 1352-4585, 6/2011, Volume 17, Issue 6, pp. 708 - 719
Tysabri | disease-modifying therapies | relapsing-remitting | multiple sclerosis | Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Neurology | Biological and medical sciences | Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis | Medical sciences | Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases | Natalizumab | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Multiple Sclerosis, Relapsing-Remitting - diagnosis | Young Adult | Antibodies, Monoclonal, Humanized | Leukoencephalopathy, Progressive Multifocal - chemically induced | Time Factors | Product Surveillance, Postmarketing | Adult | Female | Registries | Multiple Sclerosis, Chronic Progressive - drug therapy | Disability Evaluation | Severity of Illness Index | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Treatment Outcome | Sweden - epidemiology | Leukoencephalopathy, Progressive Multifocal - mortality | Neuropsychological Tests | Multiple Sclerosis, Chronic Progressive - diagnosis | Analysis of Variance | Multiple Sclerosis, Chronic Progressive - mortality | Adolescent | Multiple Sclerosis, Relapsing-Remitting - mortality | Aged | Immunologic Factors - adverse effects | Immunologic Factors - therapeutic use | Index Medicus | MEDICIN OCH HÄLSOVETENSKAP | MEDICAL AND HEALTH SCIENCES | Neurologi | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No
by Hillert, Jan
Multiple sclerosis, ISSN 1352-4585, 1/2013, Volume 19, Issue 1, pp. 26 - 28
Neurosciences | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Natalizumab | Administration, Oral | Humans | Immunologic Factors - administration & dosage | Interferons - adverse effects | Glatiramer Acetate | Clinical Trials as Topic | Peptides - administration & dosage | Interferons - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Immunologic Factors - adverse effects | Peptides - adverse effects | Multiple Sclerosis - drug therapy | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Treatment decisions in multiple sclerosis-insights from real-world observational studies
by Trojano, Maria and Tintore, Mar and Montalban, Xavier and Hillert, Jan and Kalincik, Tomas and Iaffaldano, Pietro and Spelman, Tim and Sormani, Maria Pia and Butzkueven, Helmut
Nature reviews. Neurology, ISSN 1759-4758, 02/2017, Volume 13, Issue 2, pp. 105 - 118
Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Science & Technology | Decision-making | Multiple sclerosis | Care and treatment | Health aspects | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Smoking and multiple sclerosis susceptibility
by Anna Karin Hedström and Jan Hillert and Tomas Olsson and Lars Alfredsson
European journal of epidemiology, ISSN 0393-2990, 1/2013, Volume 28, Issue 11, pp. 867 - 874
Secondhand smoke | Residential areas | Smoking cessation | Dose response relationship | Multiple sclerosis | Lungs | Ancestry | NEUROEPIDEMIOLOGY | Cigarette smoking | Cigarettes | Age | Public Health | Medicine & Public Health | Infectious Diseases | Oncology | Cardiology | Epidemiology | Case–control study | Smoking | Case-control study | Life Sciences & Biomedicine | Public, Environmental & Occupational Health | Science & Technology | Neurology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Toxicology | General aspects | Miscellaneous | Biological and medical sciences | Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis | Medical sciences | Tobacco, tobacco smoking | Smoking - adverse effects | Confidence Intervals | Age Factors | Humans | Middle Aged | Male | Multiple Sclerosis - epidemiology | Case-Control Studies | Socioeconomic Factors | Time Factors | Adult | Female | Odds Ratio | Disease Susceptibility | Risk Factors | Genotype | Logistic Models | Multiple Sclerosis - genetics | Smoking Cessation - statistics & numerical data | Sweden - epidemiology | Tobacco Use Disorder - complications | Age of Onset | Tobacco Use Disorder - epidemiology | Multiple Sclerosis - etiology | Population Surveillance | Neurosciences | Risk factors | Index Medicus | Neuroepidemiology | Hälsovetenskap | Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi | Klinisk medicin | Medicin och hälsovetenskap | Reumatologi och inflammation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry
by Spelman, Tim and Frisell, Thomas and Piehl, Fredrik and Hillert, Jan
Multiple sclerosis, ISSN 1352-4585, 7/2018, Volume 24, Issue 8, pp. 1087 - 1095
Rituximab | propensity score matching | disability progression | treatment persistence | relapse | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Disease Progression | Interferon-beta - therapeutic use | Rituximab - therapeutic use | Sweden | Glatiramer Acetate - therapeutic use | Adult | Female | Registries | Immunologic Factors - therapeutic use | Multiple sclerosis | Interferon | Copolymer 1 | β-Interferon | Patients | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Smoking and Epstein-Barr virus infection in multiple sclerosis development
by Hedstrom, Anna Karin and Huang, Jesse and Brenner, Nicole and Butt, Julia and Hillert, Jan and Waterboer, Tim and Kockum, Ingrid and Olsson, Tomas and Alfredsson, Lars
Scientific reports, ISSN 2045-2322, 07/2020, Volume 10, Issue 1, pp. 10960 - 10960
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Epstein-Barr Virus Nuclear Antigens - immunology | Infectious Mononucleosis - complications | Immunoglobulin G - blood | Humans | Middle Aged | Risk Factors | Herpesvirus 4, Human - immunology | Male | Multiple Sclerosis - epidemiology | Antibodies, Viral - blood | Case-Control Studies | Young Adult | Sweden | Adolescent | Adult | Epstein-Barr Virus Infections - complications | Female | Registries | Aged | Multiple Sclerosis - etiology | Tobacco Smoking - adverse effects | Multiple sclerosis | Mononucleosis | Antibodies | Population studies | Infections | EBNA-1 protein | Infectious mononucleosis | Risk factors | Smoking | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights